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ABSTRACT
Objective: To investigate the length of time taken to
open UK research sites in multicentre clinical trials and
to identify reasons for any delays.
Design: A case study, recording key milestone dates
from the time a site receives ethical approval through
to opening to recruitment. Delay reasons were
prospectively logged by trial staff at a minimum of
fortnightly periods using a coding system.
Setting: SANADII, a phase IV pragmatic trial,
managed by the Clinical Trials Research Centre,
Liverpool. The trial seeks to work with over 100
National Health Service (NHS) sites to meet its
recruitment target of 1510 patients.
Outcomes and analysis: The primary outcome was
time from Multicentre Regional Ethics Committee
(MREC) approval to site opening using survival
analysis. Where sites took over a specified time to
reach milestones (>3 months from MREC to Site
Specific Information (SSI) submission, >30 days from
SSI validation to local R&D approval, or >30 days from
local Research and Development (R&D) approval to
opening to recruitment), the longest continuous delay
during that milestone was identified.
Results: The median opening time for participating
sites was 9.7 months (IQR 6.2 to Not Reached). SSI
submission took 7 months (IQR 4.1–12.3) from ethics
approval, R&D approval took 16 days (IQR 5.0–32.0)
from SSI validation and site opening took 15 days (IQR
8.5–40.0) following R&D approval. The longest delays
before SSI submission resulted from negotiating
excess treatment costs, finalising logistics, collecting
CVs and ongoing participation discussions.
Conclusions: While recently imposed targets are
reducing the time taken for R&D departments to
approve valid applications, the time taken to open UK
research sites remains excessive and must be reduced.
At present significant public funds are being used
inefficiently in order to navigate NHS systems,
challenging the resolve of trial teams and the
competitiveness of the UK.
BACKGROUND
Many researchers have communicated frustra-
tion at the length of time taken to open
research sites in multicentre clinical trials,
which increases the cost to funders and
makes the UK a less attractive location to
conduct research.1 2 The current governance
process for UK clinical trials requires approval
from an ethics committee (and other regula-
tory authorities depending on the interven-
tion), as well as obtaining separate local
Research and Development (R&D) approval
from every National Health Service (NHS)
trust that will recruit patients. With individua-
lised applications and separate review pro-
cesses, the local NHS trust approvals are
increasing the cost and complexity of initiat-
ing clinical trials.3 A parliamentary report on
clinical trials in September 2013 highlighted
separate local NHS R&D approvals as the
biggest barrier to initiating clinical trials in
the UK and one of the factors that led to a
22% decline in the number of clinical trials
conducted in the UK between 2007 and
2011.4
To obtain local R&D approval a named
principal investigator and site need to be sub-
mitted to ethics through the Integrated
Strengths and limitations of this study
▪ The prospective evaluation of time taken to open
UK research sites using clearly defined milestone
dates and coded delay reasons allows a detailed
analysis of the current barriers to initiating trials
in the UK.
▪ We identified that current targets are reducing
the time taken to approve local National Health
Service (NHS) applications but that the overall
time remains excessive.
▪ The identification of delay reasons can strongly
contribute to discussion around the Health
Research Authorities development of a single
approval system.
▪ The analysis of delay reasons is limited to the
perspective of the Clinical Trial Research Centre
based on information available from day to day
trial management.
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Research Application System (IRAS) either as part of the
original trial application or as a substantial amendment
afterwards. While processing it as a substantial amend-
ment can be a little onerous, approval letters are usually
issued within a matter of days.
Following this a Site Speciﬁc Information (SSI) Form
needs to be completed within IRAS summarising the
trial, what local resources are needed and who will be
involved. Supporting documents are attached such as
Patient Information Sheets (PIS) and Consent Forms
containing the trust logo, and CVs of all site staff per-
forming trial duties. Once the principal investigator has
signed the completed SSI it is electronically submitted
to the relevant R&D department in England or manu-
ally emailed to trusts in constituent nations who do not
use the IRAS system.
The time taken for local R&D departments to approve
the application has been the primary focus of criti-
cism.1 3 5–7 In 2011 Whitehead et al7 reported that
approval took between 6 and 197 days (mean 42 days)
from SSI submission. In 2007 Al-Shahi Salman6 retro-
spectively interviewed R&D departments from four trials
and identiﬁed a median delay of 44 working days (IQR
23.0–80.0). With inconsistent approaches across trusts,
duplication of ethical review and unclear delays the
research community called for agreed timeframes to be
imposed on R&D departments.1 6 8
In 2011 the government introduced NHS contract
benchmarks to incentivise trusts to recruit the
ﬁrst patient within 70 days of receiving a valid SSI
application.9 Alongside this, internal targets from the
NIHR Clinical Research Network (NIHR CRN)
required English trusts to approve valid applications
within 30 days. These internal NIHR CRN targets con-
tributed to the public High Level Objectives that
include a median approval time across all trial sites
of 40 days.
This study seeks to prospectively assess the time taken
to open UK research sites now these targets are in place
and identify reasons for any remaining delays.
METHODS
SANADII (http://www.sanad2.org.uk) is a phase IV
pragmatic study comparing standard and new treatments
for patients with epilepsy, which aims to recruit 1510 par-
ticipants over the age of 5 from over 100 sites across all
four constituent nations of the UK.
The trial follows routine care for newly diagnosed epi-
lepsy patients, with the exception that patients complete
a postal questionnaire at 3 and 6 months in the ﬁrst
year, and annually thereafter. Patients are followed up
for two to ﬁve and a half years depending on when they
are recruited into the trial.
The additional cost of patients receiving the new
drugs compared with the standard drugs (the Excess
Treatment Costs), have been calculated at an average
total cost of £1182 per patient.
SANADII is funded by the NIHR Health Technology
Assessment Programme (HTA), cosponsored by the
University of Liverpool and The Walton Centre and is
managed by the Clinical Trials Research Centre (CTRC)
within the University of Liverpool. SANADII funding was
conﬁrmed on the 17 May 2011 (subject to contract).
The ethics application was submitted on 18 April 2012
and received approval on 7 June 2012.
During data collection the study had a full time trial
coordinator from March 2012 and up to three trial coord-
inator assistants, all of whom were involved in opening
research sites. Alongside this the NIHR Medicine for
Children Research Network, the NIHR Dementias and
Neurodegeneration Research Network and the Welsh
Epilepsy Research Network allocated staff time to actively
help set up sites identiﬁed through their contacts.
Inclusion criteria
All SANADII research sites listed on the original ethics
trial application or any subsequent additional sites were
included in the data collection. This included 17 ori-
ginal SANADII sites that received ethical approval in
June 2012, and another 111 sites added in 2013 across
four ethics amendments (3 January 2013, 3 April 2013,
15 July 2013 and 26 November 2013).
A number of NHS trusts who planned to recruit both
children and adults requested that paediatric and adult
research teams apply for separate R&D approval as there
was little or no interaction between them due to geog-
raphy or clinic schedules. Where teams completed separ-
ate SSI forms for the same trust, they have been
analysed as separate sites.
Data collection
SANADII trial management staff were trained by the
authors to record key milestone dates in a purpose built
web database. Data were collected from the date a site
received ethics approval until they no longer wished to
participate or they opened to recruitment (ﬁgure 1).
Alongside milestone dates trial staff also recorded delay
reasons using a coding system created to cover a variety
of potential issues across all stages of the site set up
process (see online supplementary table S1). CTRC staff
were required to enter a minimum of one delay reason
a fortnight, but could enter up to three delays at any
given point. They were encouraged to enter the same
codes until the delay was resolved or other delays were
perceived to have a greater impact on trial site progress.
Key site characteristics were logged such as the con-
stituent nation, whether they were recruiting adults, chil-
dren or both and whether a research network was
actively working with the SANADII team to get all the
paperwork and local approvals completed.
Where research networks were working directly with
sites, trial staff would complete data entry based on fort-
nightly updates provided by the network staff.
2 Kearney A, et al. BMJ Open 2014;4:e005874. doi:10.1136/bmjopen-2014-005874
Open Access
At the point of analysis SANADII trial management
staff also provided separate data on the date the ﬁrst
patient was recruited at each site.
Milestone data for other CTRC trials initiated in 2012
and 2013 were retrospectively collected from trial
records for comparison with SANADII data.
Identifying delay reasons
Where sites took over a speciﬁed time to reach mile-
stones (>3 months from MREC to SSI submission,
>30 days from SSI validation to R&D approval, or
>30 days from R&D approval to opening to recruitment)
the longest continuous delay reason recorded between
those two milestone dates was identiﬁed.
The original data were analysed to identify the top
three longest delays for each site milestone and then
manually reviewed by one author (AK). If necessary,
emails, trial records and discussions with SANADII staff
were used to conﬁrm or revise the longest delay code.
As a result of SANADII staff working on other site set
up activities while R&D reviewed the SSI application,
delay reasons between the milestones SSI validation and
R&D approval were predominantly identiﬁed from trial
records and emails retrospectively.
Statistical analysis
Milestone validation checks and all analyses were per-
formed using SAS V.9.3. All of the outcomes were mea-
sured using a time-to-event survival analysis approach.
Sites that had not yet had observed outcomes were cen-
sored at the date of data extraction. The outcome data
were compared across factors (recruitment of children
and/or adults, hospital type, network support compared
with no network support) using Kaplan-Meier curves
and the p values from log-rank tests with relative effects
of factors summarised using median times with 95% CIs
obtained from the Kaplan-Meier plots, and HRs with
95% CIs. In addition, 25% and 75% quartiles with 95%
CIs obtained from the Kaplan-Meier analyses are pre-
sented. The study did not require ethical approval.
RESULTS
The ﬁrst trial sites received MREC approval on the 7
June 2012 and data were extracted from the database on
Figure 1 Milestones and definitions. Definitions of key milestone dates collected during the site set up process.
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the 7 March 2014. SANADII had 128 sites with ethical
approval of which 32 (table 1) had dropped out before
submitting their SSI form (18% of adult sites and 28%
of paediatric teams) leaving 96 participating sites (see
online supplementary table S2).
Overall, participating sites demonstrated a median
opening time of 10.5 months (IQR 7.3–15.2) from
MREC approval. However, the ﬁrst 17 SANADII sites,
who received ethical approval in June 2012, had a
median opening time of 14.5 months (IQR 11.4–16.0;
ﬁgure 2) as they experienced a unique 6-month delay as
excess treatment costs needed to be approved by hos-
pital trusts and primary care. With the NHS restructure
and the formation of Clinical Commissioning Groups
(CCG) only coming into effect in April 2013 no-one was
willing to review applications, putting all 17 sites on hold
until solutions began to emerge in January 2013. Fifteen
of the ﬁrst 17 sites are participating sites and conse-
quently we have excluded these 15 sites from the analysis
of the time from MREC approval to site opening. For
fourteen of these sites the delay occurred pre-SSI sub-
mission and so these 14 have also been excluded from
analysis of time from MREC approval to SSI submission.
For one site the delay was post R&D approval and so it
has been excluded from analysis of time from R&D
approval to site opening and from SSI validation to
recruiting the ﬁrst patient
The remaining 81 participating sites who received
their ethical approval throughout 2013 had a median
opening time of 9.7 months (IQR 6.2 to Not Reached)
(ﬁgure 2).
Breaking down the site set up process we observed
that the median time from MREC approval to SSI sub-
mission was 7 months (IQR 4.1–12.3), from SSI
Validation to R&D Approval 16 days (IQR 5.0, 32.0) and
from R&D Approval to opening 15 days (IQR 8.5–40.0;
ﬁgure 3). Thirty three of 45 sites (73%) received R&D
approval within 30 days of the SSI being validated (see
online supplementary table S5).
Analysis of site characteristics showed there was no dif-
ference in site opening times between teaching hospitals
and district general hospitals with medians 9.7 vs
10.0 months, HR 0.99 95% CI (0.5 to 2.0) p=0.98 (see
online supplementary ﬁgure S1). However, at any point
Table 1 SANADII site characteristics at 7 March 2014
Total sites with MREC approval: 128 (%)
Status:
Participating 96 (75)
No longer participating 32 (25)
Participating status:
(1) Had MREC approval but not yet submitted SSI 31 (32)
(2) Submitted SSI but not yet had R&D approval 8 (8)
(3) R&D approved but Green Light Checklist not yet completed 4 (4)
(4) Green Light Checklist completed but not yet open to recruitment 0 (0)
(5) Site open but not yet recruited first patient 15 (16)
(6) Site open and first patient recruited 38 (40)
Recruitment type (of those participating)
Adult 47 (49)
Paediatrics 43 (45)
Both paediatrics and adult 6 (6)
Hospital type (of those participating)
District general hospital 56 (58)
Health centre 2 (2)
Specialist paediatrics 6 (6)
Specialist tertiary 1 (1)
Teaching hospital 31 (32)
Country (of those participating)
England 76 (79)
Isle of man 1 (1)
Northern Ireland 2 (2)
Scotland 7 (7)
Wales 10 (10)
Set up actively supported by Research Network (of those participating):
NIHR Comprehensive Local Research Network (CLRN)* 4 (4)
NIHR Dementias and Neurodegeneration Network (DenDRoN)* 14 (14)
NIHR Medicines for Children Research Network (MCRN)* 24 (25)
Welsh Epilepsy Research (WERN) 6 (6)
No Network 48 (50)
*Networks within NIHR Clinical Research Network before it was restructured in April 2014.
MREC, Multicentre Regional Ethics Committee; SSI, Site Specific Information; R&D, Research and Development.
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paediatric sites were opening twice as quickly as adult
sites with medians; 8.5 months vs Not Reached; HR 2.33
(95% CI 1.1 to 4.8); p=0.02 (see online supplementary
ﬁgure S1). This may have been inﬂuenced by the strong
backing of the NIHR Medicine for Children’s Research
Network (MCRN) who coadopted the trial. The NIHR
MCRN network was one of the three networks who dedi-
cated staff time to help open sites and engaged their
Local Research Networks to help nationally. Twenty-ﬁve
paediatric sites (60% of all paediatric sites) compared
with 14 adult sites (40% of all adult sites) had active
network support.
Of the 69 sites that took over 3 months to submit their
SSI form the most frequent continuous delays were
negotiating excess treatment costs (n=16), ﬁnalising
logistics at site (n=11), collecting research Curriculum
Vitae (CVs) (n=10) and ongoing participation discussion
(n=10). During data collection SANADII staff were
aware that some R&D departments were holding off SSI
submission in order to review trials before they were for-
mally submitted and to meet their targets. R&D depart-
ments holding off submission accounted for the longest
delay in ﬁve sites (table 2).
Of the 12 sites that took over 30 days to be granted
R&D approval, waiting for the contract to be signed by
site (n=3) and unexplained delays (n=3) were the most
frequent reasons (table 2).
Eighteen sites took longer than 30 days to open to
recruitment from R&D approval with most frequent
reasons including getting the delegation log signed
(n=5), waiting for training on trial procedures (n= 4),
and waiting for the contract to be signed by site (n=2).
In another two sites the R&D approval letter itself held
up site opening when it was sent to trial staff a month
after it was issued (table 2).
The median time for recruiting the ﬁrst patient from
SSI validation was 127 days (IQR 64.0–230.0) which is
signiﬁcantly more than the 70 day contract benchmark
(see online supplementary ﬁgure S2). Only 12 of 40
sites (30%) that have recruited their ﬁrst patients did so
within 70 days of SSI validation (see online supplemen-
tary table S5). Delay reasons were not formally collected
after the site was open to recruitment. However, as part
of the trial management process sites were contacted to
see if there were any problems with recruitment. In
general sites were not able to give a deﬁnitive reason
why there was a delay but responses included a lack of
eligible patients, holidays or that there was no problem
and they would recruit patients shortly. However, new
epilepsy is a common presentation and trial follow-up
was assessed through routine care, so recruiting patients
should be relatively quick and easy in comparison to
many other trials.
Milestone data were retrospectively collected for
another four CTRC studies and compared with SANADII
demonstrating that in terms of the time to open sites,
these ﬁndings are not unique (see online supplementary
ﬁgure S3). The cohort of studies includes a medical
device trial (BASICS), another drug trial (TAILOR), a
microbiology study (DINOSAUR Micro.) and a service
Figure 2 Survival analysis of time from MREC approval to site open to recruitment for participating sites (months). Numbers at
risk are displayed above the x axis. Two of the 17 sites which received ethical approval in 2012 and 30 of the 111 sites who
received ethical approval in 2013 have been excluded from the analysis as they are no longer participating. NR= not reached. For
the full Kaplan-Meier summary see online supplementary table S3.
Kearney A, et al. BMJ Open 2014;4:e005874. doi:10.1136/bmjopen-2014-005874 5
Open Access
evaluation (DINOSAUR SE), for which site set up started
in 2012 or 2013. The lowest median opening time was
5.3 months (IQR 4.8–7.4) which was for the service evalu-
ation which did not require local R&D approval.
DISCUSSION
Principal findings
Government initiated targets and NIHR CRN initiatives
are impacting the time taken to gain local R&D approval
from submission of valid documentation. Where previ-
ously researchers were left waiting an indeterminate
amount of time, the median approval has been reduced
from around 40–45 days to 16 days with 73% of applica-
tions being approved within 30 days. Researchers now
have an understanding of when they are likely to receive
approval and so can proactively align other activities to
ensure that sites open to recruitment shortly afterwards.
However, it is concerning that despite R&D depart-
ments approving applications more quickly, sites
still took more than 9 months to open with the majority
of time spent preparing to submit the application
form. The most frequent reason identiﬁed before SSI
submission was negotiating excess treatment costs
which was the longest delay in 16 (23%) sites but also
contributed to delays in 39 (48%) sites with MREC dates
in 2013.
Excess treatment costs are the difference in cost
between the investigative treatments in a trial and stand-
ard care. The NHS is required to cover normal treatment
costs, but additional costs incurred by trials (including
service support costs and research costs) need to be cor-
rectly attributed to either research funders or speciﬁc
trust or CCG budgets. Previous authors have highlighted
attributing and negotiating costs as a cause for delays in
setting up research sites.3 6 7
Figure 3 Survival analysis of time between milestones for participating sites. Numbers at risk are displayed above the x axis.
Time from MREC to SSI Submission: 15 of the 96 participating sites have been excluded from the analysis because 14 of them
experienced unique delays due to the NHS restructure and 1 site has a missing SSI submission date. NR= not reached. Time
from SSI validation to R&D Approval: 50 of the 96 participating sites have been excluded from the analysis. Thirty-one sites have
not submitted the SSI form, 7 have submitted SSI form and not received R&D approval yet but have a missing SSI validation
date, 11 have received R&D approval but have a missing SSI validation date and 1 site has a negative time due to technical
issues with IRAS. Time from R&D Approval to Site opening: 40 of the 96 participating sites have been excluded because 39 sites
have not reached R&D approval and 1 site with ethical approval in 2012 was excluded as they experienced unique delays due to
the NHS restructure. For the full Kaplan-Meier summary tables see online supplementary table S4.
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On several occasions trial staff were asked to help cal-
culate costs, prepare funding applications and give
advice on how to resolve excess treatment costs. While
the Department of Health’s AcoRD guidance10 is useful
in deﬁning the different types of research costs and who
is broadly responsible for them it seems to have done
little to ease the problem in practice. Dr Greta
Westwood recently wrote in the Health Services Journal,
‘Successive policy documents remind NHS organisations
of the duty to fund excess treatment costs, yet no
national scheme exists to manage them’.11
Finalising site logistics and ongoing participation dis-
cussion together accounted for the longest delay in 21
(30%) sites. Both of these highlight the challenges of
working with busy healthcare professionals who have
competing priorities. It has been suggested that the level
of data collection required under the current governance
process is unmanageable for clinicians and should be
revised to prevent a decline in participation.12 Finalising
site logistics mainly compromised of delay codes about
SSI completion. However, in SANADII the majority of the
SSI form was prepopulated before sending to clinical staff
Table 2 Frequency of longest continuous delay reasons for SANAD-II sites that took over a specified time to complete
milestones
MREC to SSI Submission >3 months
Excess Treatment Cost Negotiation 16
Finalising logistics ie, SSI completion, identifying staff* 11
Collecting CVs 10
Participation Discussions: ie change of PI, ongoing feasibility† 10
Not a priority site for SANADII staff‡ 7
Awaiting R&D permission to submit SSI§ 5
Waiting for PI to sign SSI 3
Resolving R&D query/s 2
Pharmacy approval 1
Local ethics 1
Site research team holding off set up¶ 1
No news from network 1
No response to email** 1
69
SSI Validation to R&D Approval >30 days
Waiting for contract to be signed by site 3
Unknown delay 3
Waiting for training on trial procedures 1
Contract being signed by sponsor 1
Contract review by site 1
Excess Treatment Cost Negotiation 1
Governance query 1
Waiting for staff to come into post 1
12
R&D Approval to Opening > 30 days
CTU waiting for completed delegation log 5
Waiting for training on trial procedures 4
Waiting for site to sign contract 2
Waiting for R&D approval letter 2
CTU waiting for Acknowledgement receipt of Essential Documents 1
Waiting for sponsor to sign contract 1
Waiting for staff to come into post 1
Waiting for staff to do GCP training 1
No response to email§ 1
18
Where some delay reasons have been grouped the text in italics indicates the most frequent codes used in the grouping. The wording of
some delay code names for smaller frequencies have been adapted to give better understanding of the actual delays based on notes made at
data collection.
*Included SSI completion (n=9), identifying staff (n=1) and agreeing recruitment target (n=1).
†Included change of PI (n=8), feasibility discussions (n=1), decided not to participate but are now participating again (n=1).
‡This reason increased from interim analysis in October due to the reduction in staff (trial coordinator assistants) towards the end of 2013. As
a result trial staff prioritised proactive sites and weren’t able to follow-up less proactive or new sites.
§R&D holding off submission possibly due to internal issues (n=1), R&D were reviewing the SSI before formal submission (n=3) and research
network informed us they were waiting for R&D permission to submit the SSI (n=1).
¶Research staff at site did not have capacity and requested that contact be re-established in 3 months.
**No response from clinical staff.
CVs, Curriculum Vitaes; SSI, Site Specific Information; R&D, Research and Development.
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for review but could take up to several weeks or even
months to complete. This perhaps reﬂects the time
needed to discuss the trial with managers and affected
departments (eg, pharmacy), agree stafﬁng and conﬁrm
capacity, all of which needs to be documented in the SSI
form. Ongoing participation discussion included delay
codes for feasibility assessments post-ethical approval and
changes of Principal Investigators. We found a number of
Principal Investigators decided not to participate requir-
ing us to identify replacements and gain new ethics
approval before submitting the SSI, all adding to the time
needed to open the site.
The third most signiﬁcant delay reason was collecting
research CVs. IRAS guidance requires that short research
CVs are attached to the application for anyone who will
perform trial related duties. However, our experience
shows it can take months to collect these from research
staff. According to Good Clinical Practice guidelines, CVs
of investigators and subinvestigators should be collected
and ﬁled by both the site and sponsor before the trial
commences to ‘document qualiﬁcations and eligibility to
conduct a trial and/or provide medical supervision of
participants’.13 Our concern is that sponsors or clinical
trial units (under delegated authority from the sponsor)
are unable to and do not formally assess this despite col-
lecting CVs. We believe consideration should be given to
a process in which the employing trust is responsible for
conﬁrming that site staff are suitably qualiﬁed and ensure
they hold adequate documentation to demonstrate this.
In the case of HTA funded trials such as SANADII, signiﬁ-
cant resource is spent on staff in order to negotiate NHS
systems, which is very difﬁcult to justify in a system with
limited resources that must be spent wisely. It is worth
noting that the CTRC invested a larger number of staff
hours than had been accounted for in the grant application
to help facilitate site opening. From January to October
2013 SANADII had a full time trial coordinator and the
equivalent of three full time trial coordinator assistants
whose main priority was to open sites. This was reduced to
one coordinator and the equivalent of one full time assist-
ant towards the end of 2013 due to funding constraints.
SANADII also received strong support from a number of
topic speciﬁc research networks, three of whom dedicated
staff time to opening sites alongside the SANADII staff.
Despite this investment it still took on average
9.7 months to open sites and the ofﬁcial start of the trial
was delayed by 4 months. While the trial is currently
exceeding its original recruitment schedule and is not
likely to need a time extension, many other studies
have14 15 and the costs of managing delays are being
passed onto funders. Future grant applications will need
to build in increased stafﬁng costs if the governance
process is not successfully streamlined.
Meaning of the study: possible explanations and
implications for clinicians and policymakers
On the 31 March 2014, the Health Research Authority
(HRA) announced that they had approval to continue
streamlining the governance process and implement a
single application system16 as recommended in the
Academy of Medical Science Review.17 The HRA’s
summary plan support the results of this study stating
‘Although these targets and benchmarks have been suc-
cessful in driving reductions in timelines, the metrics for
REC and R&D systems are in isolation, and analysis now
shows that without integration there is risk that any
further downward pressure on timelines will simply
move delays around the system’.18
The HRA plans to incorporate ethical review and the
legal aspects of the current R&D approval process at sites
into one global permission. They believe this will remove
a lot of repetition at a local level and instead will give
trusts more time to work on setting up of the study.18
This is a welcome development but to successfully
reduce clinical governance times the authors encourage
review of the issues raised in this report. It is essential
that any change of governance not only revise how
approval is obtained, but also holistically consider what
documents and processes are needed. Under the new
streamlined process local site permission will still need
to be granted based on capacity and research CVs will
still need to be collected prior to study start under Good
Clinical Practice (GCP) and International Conference of
Harmonisation (ICH) guidelines. A change to trusts
centrally holding and disseminating up-to-date research
CVs may be one pragmatic solution.
Strengths and weaknesses of the study
Milestones were clearly deﬁned (ﬁgure 1) at the start
and data was manually reviewed against stored docu-
ments with validation checks in SAS used to minimise
data entry errors. Consequently the milestone data pro-
vides a reliable, objective basis for analysing time taken
to open research sites.
The study is limited in that it recorded the CTRC’s
perspective of delays. We have not requested reasons
from clinical staff or R&D departments other than
would normally occur in day to day trial management.
Similarly the process of choosing delay reasons was sub-
jective although trial management staff were trained to
enter data consistently.
Delay reasons for SSI validation to R&D approval
should be interpreted with some caution due to the lack
of communication from R&D departments about pro-
gress when reviewing the application.
Unanswered questions and future research
If HRA performance targets become based on time
from ethical submission to opening sites there is a
potential danger that delays may simply be shifted to an
earlier part of the process as seen with the introduction
of the NHS contract benchmarks. Delaying ethics sub-
mission in order to meet targets would be particularly
challenging for researchers as many funders only begin
releasing grant awards on receipt of ethical approval.
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Future research will need to review site opening times
and delays from grant awards onwards in order to assess
the effect of the HRA’s new streamlined approval process.
This case study provides a good baseline to evaluate
the true impact of future changes by the HRA. It would
be beneﬁcial to repeat the study in a few years to
compare results and assess whether timeframes have
increased or diminished.
CONCLUSION
Reducing the length of time needed to set up clinical
research sites in multicentre studies continues to be a
high priority in order for the UK to remain a competi-
tive market for research.
The HRA’s proposed streamlining into a single appli-
cation is a clear step forward, but is awaited with a sense
of caution to see what difference it will make given the
nature of the delays identiﬁed in this study.
Alongside governance changes a number of issues
need to be addressed including implementing a
clear strategy to manage excess treatment costs in an
increasingly budget constricted NHS. The collection of
research CVs needs reviewing in order to truly achieve
the desired effect of protecting patients without burden-
ing busy clinicians with unproductive paperwork. Finally
additional resources need to be invested into helping
clinical staff and hospital management quickly and
decisively incorporate trials into their ongoing workﬂow.
This study highlights the current variety of delays that
affect trial site set up and the impact that these have on
the use of resources and grant funding. To make signiﬁ-
cant reductions in site opening times will require under-
standing, close co-operation and investment from a wide
range of stakeholders including NHS Trust and CCG gov-
ernance staff, clinical staff, the HRA and the newly restruc-
tured NIHR Clinical Research Networks all of whom can
inﬂuence and support different aspects of the process.
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